Multinationals Dispute Deposits Demanded By Jiangsu Hospital
This article was originally published in PharmAsia News
Executive Summary
A major hospital in China has started asking drug makers to put down cash deposits or face suspension, is it a desperate measure from cash-constrained hospitals or legitimate request based on supply contracts? Legal experts share views on the thorny issue.
You may also be interested in...
2016 Review: Rapid Change Defines China Regulatory Environment
If you missed some of the many significant events in China’s policy and regulatory landscape in 2016, here is your opportunity to catch up on month-by-month developments.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.